Email updates

Keep up to date with the latest news and content from BMC Medicine and BioMed Central.

Journal App

google play app store
Open Access Commentary

Peroxiredoxin 4: a multifunctional biomarker worthy of further exploration

Janin Schulte

Author Affiliations

Department of Research and Development, BRAHMS GmbH, Part of Thermo Fisher Scientific, 16761 Hennigsdorf, Germany

BMC Medicine 2011, 9:137  doi:10.1186/1741-7015-9-137

Published: 23 December 2011

Additional files

Additional file 1:

Peroxiredoxin 4 in clinical indications. This overview does not presume to be complete. Indeed, cited cancer settings are limited to subgroups with important clinical findings beyond changes in peroxiredoxin 4 expression. Unless otherwise mentioned, the term 'Prx4' refers to intracellular protein levels.

Format: DOC Size: 62KB Download file

This file can be viewed with: Microsoft Word Viewer

Open Data